Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported interim Phase 1/2a results for ARO-INHBE, an RNAi therapy for obesity and MASH, at EASL 2026. Treatment produced clinically meaningful liver fat reductions as monotherapy and with low-dose tirzepatide, with up to 85.3% mean maximum Activin E reduction and effects beyond 3 months.
Patients with obesity and baseline liver fat content above 8% receiving ≥200 mg ARO-INHBE showed a placebo-adjusted 44% liver fat reduction. According to Arrowhead, ARO-INHBE was generally well tolerated, with mostly mild adverse events and no treatment-related discontinuations reported to date.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented new clinical data on plozasiran at the 94th European Atherosclerosis Society Congress.
A single 25 mg dose showed similar APOC3 and triglyceride reductions in subjects with moderate-to-severe renal or moderate hepatic impairment versus controls, supporting use without dose adjustment. A separate case report linked preconception exposure to sustained triglyceride lowering during pregnancy.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal 2026 second quarter results for the period ended March 31, 2026, and hosted a May 7, 2026 webcast.
Highlights: commercial launch momentum for REDEMPLO (plozasiran) with >400 prescriptions to date and ~180 patients shipped; updated U.S. WAC to $45,000 per patient per year; multiple regulatory approvals and CHMP positive opinion; initiated dosing in a first-in-human dual-target RNAi candidate; completed concurrent public offerings raising $930 million gross proceeds.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) licensed ARO-PNPLA3 to Madrigal Pharmaceuticals in an exclusive global agreement announced May 5, 2026. Phase 1 data published in The New England Journal of Medicine showed up to 46% liver fat reduction in PNPLA3 I148M homozygous patients.
Financial terms: $25 million upfront, up to $975 million in milestones, and tiered royalties in the high-single digits to mid-teens.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple investor and scientific events across May 2026, including BofA Healthcare (May 12-14), TIDES USA (May 11-14), ECO 2026 (May 12-15), RBC Capital Markets (May 19-20), EAS 2026 (May 24-27) and EASL 2026 (May 27-30).
Presentations cover RNAi therapeutics, MAPT/tau suppression, activin E and metabolic dysfunction, plozasiran clinical data, and ARO-INHBE liver-fat results. Materials and webcasts will be available on the company Events and Presentations investor page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced TGA approval of REDEMPLO (plozasiran) in Australia for adult patients with familial chylomicronemia syndrome (FCS) whose standard triglyceride‑lowering therapies were inadequate. REDEMPLO is the first approved FCS medicine in Australia and is given subcutaneously once every three months.
The approval cites Phase 3 PALISADE data showing a median 80% triglyceride reduction with 25 mg and an 83% lower odds of acute pancreatitis in pooled dose groups versus placebo; common adverse reactions include hyperglycaemia (12.8%).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) received a positive CHMP opinion recommending approval of REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The CHMP based its opinion on Phase 3 PALISADE data showing a median 80% triglyceride reduction and fewer acute pancreatitis cases versus placebo. The European Commission decision is expected in Q2 2026; REDEMPLO is self-administered subcutaneously every three months and carries known adverse reactions including hyperglycaemia (12.8%).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will webcast its fiscal 2026 second quarter results on May 7, 2026 at 4:30 p.m. ET. The company will host a live audio webcast and conference call to discuss results for the quarter ended March 31, 2026.
Investors can access the live webcast on Arrowhead's Events and Presentations page; a replay will be available about two hours after the call. Analysts must register to receive dial-in details and a personalized PIN to join the conference call.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported two-year open-label extension data for plozasiran in hypertriglyceridemia presented at ACC.26 on March 28, 2026. Patients with severe HTG saw a median -83% triglyceride reduction; 96% achieved TG <500 mg/dL. No adjudicated acute pancreatitis events occurred across the 2-year OLE.
Durable reductions were also observed in remnant cholesterol, non-HDL cholesterol, and ApoB with a safety profile consistent with earlier trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple investor events in March 2026, including TD Cowen, Leerink, Jefferies Biotech on the Beach, and Barclays conferences.
Scheduled appearances include fireside chats, investor dinners, and 1x1 meetings between March 2–11, 2026; presentation materials and webcasts will be posted on the company's Investors Events and Presentations page.